Terminated PHASE2 INTERVENTIONAL 1-arm NCT00416884

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Fludarabine, Campath, TBI T-Cell Deplete NMSCT With Post-Transplant T-Cell Infusions for CML Failing Imatinib Therapy With Imatinib (STI571)

Sponsor: National Cancer Institute (NCI)

Conditions Leukemia

Interventions Campath Fludarabine T-Cell Deplete Total Body Irradiation (TBI)

Updated 7 times since 2017 Last updated: Sep 25, 2017 Started: May 31, 2003 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Leukemia trials with similar outcome

Browse all Leukemia trials

A PHASE2 clinical study on Leukemia, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
OHSU Knight Cancer Institute

Data source: OHSU Knight Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States